{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:52:33Z","timestamp":1780987953476,"version":"3.54.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The treatment landscape of B-cell non-Hodgkin lymphoma (B-NHL) has been rapidly transformed by the emergence of T-cell engaging (TCE) therapies. Within the past decade, anti-CD19 chimeric antigen receptor (CAR) T-cell therapies have moved from relapsed\/refractory to second-line settings in aggressive large B-cell lymphomas and are now also approved for R\/R follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. More recently, bispecific antibodies with dual engagement of CD20\u200a\u00d7\u200aCD3 have emerged as an alternative TCE option with regulatory approval as monotherapies in several relapsed\/refractory B-cell lymphomas. Common investigational themes for TCE therapies include earlier integration in the treatment paradigm, testing combination approaches, and considering optimal sequencing approaches. Despite major progress, there remains opportunity for technical innovations that may improve efficacy, attenuate toxicity, and ease the sometimes complex logistics around treatment delivery. Alternative and multiantigen targets are being explored in CAR T-cell constructs as well as bispecific antibodies, with some of these approaches now in early-phase clinical trials. Strategies to improve CAR T manufacturing, optimize T-cell fitness, and design novel \u201carmored\u201d CAR T-cells designs are actively being tested in preclinical and early-phase clinical data. From a safety perspective, much progress has been made in reducing the burden of side effects and broadening access; however, barriers remain before TCE therapies can be widely available to all patients. This brief review addresses some of the latest strategies being tested to elevate TCE therapies as pillars of immunotherapy for B-NHL.<\/jats:p>","DOI":"10.1182\/hematology.2025000722","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:08:33Z","timestamp":1764943713000},"page":"334-341","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight"],"prefix":"10.1182","volume":"2025","author":[{"given":"Alexandra E.","family":"Rojek","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"7","key":"2025120616332708300_hem2025000722C1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2025120616332708300_hem2025000722C2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"10343","key":"2025120616332708300_hem2025000722C3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"26","key":"2025120616332708300_hem2025000722C4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120616332708300_hem2025000722C5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025120616332708300_hem2025000722C6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2025120616332708300_hem2025000722C7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025120616332708300_hem2025000722C8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"14","key":"2025120616332708300_hem2025000722C9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10402","key":"2025120616332708300_hem2025000722C10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"24","key":"2025120616332708300_hem2025000722C11","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"2025120616332708300_hem2025000722C12","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025120616332708300_hem2025000722C13","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"8","key":"2025120616332708300_hem2025000722C14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025120616332708300_hem2025000722C15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/ refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10466","key":"2025120616332708300_hem2025000722C16","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"issue":"15","key":"2025120616332708300_hem2025000722C17","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood.2024026830","article-title":"Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial","volume":"145","author":"Brody","year":"2025","journal-title":"Blood"},{"issue":"10450","key":"2025120616332708300_hem2025000722C18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lancet"},{"issue":"511","key":"2025120616332708300_hem2025000722C19","doi-asserted-by":"crossref","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci Transl Med."},{"issue":"23","key":"2025120616332708300_hem2025000722C20","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-19-1337","article-title":"Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without cotargeting CD19","volume":"25","author":"Ormh\u00f8j","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"34","key":"2025120616332708300_hem2025000722C21","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1038\/s41388-022-02416-5","article-title":"ROR1-targeting switchable CAR-T cells for cancer therapy","volume":"41","author":"Peng","year":"2022","journal-title":"Oncogene"},{"issue":"16","key":"2025120616332708300_hem2025000722C22","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.1200\/JCO.2024.42.16_suppl.6534","article-title":"PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease","volume":"42","author":"Budde","year":"2024","journal-title":"J. Clin. Oncol"},{"issue":"suppl 1","key":"2025120616332708300_hem2025000722C23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood-2024-193681","article-title":"Evaluation of AZD0486, a novel CD19xCD3 T-cell engager, in relapsed\/refractory diffuse large B-cell lymphoma in an ongoing first-in-human phase 1 study: high complete responses seen in CAR-T-naive and CAR-T-exposed patients","volume":"144","author":"Gaballa","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025120616332708300_hem2025000722C24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2024-208539","article-title":"Interim results from a phase 2 pivotal study (DALY II USA) of tandem CD20-CD19-directed non- cryopreserved CAR-T cells\u2014zamtocabtagene autoleucel (zamto-cel) in patients with relapsed\/refractory Diffuse Large B Cell Lymphoma","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"issue":"20","key":"2025120616332708300_hem2025000722C25","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1200\/JCO-24-02158","article-title":"Phase I\/II study of adaptive manufactured Lentiviral anti-CD20\/anti-CD19 chimeric antigen receptor T cells for relapsed, refractory mantle cell lymphoma","volume":"43","author":"Shah","year":"2025","journal-title":"J Clin Oncol"},{"issue":"13","key":"2025120616332708300_hem2025000722C26","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"issue":"18","key":"2025120616332708300_hem2025000722C27","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025120616332708300_hem2025000722C28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2024-204264","article-title":"Rapcabtagene autoleucel (YTB323) in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL): phase II trial clinical update","volume":"144","author":"Riedell","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2025120616332708300_hem2025000722C29","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov"},{"issue":"12","key":"2025120616332708300_hem2025000722C30","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"7951","key":"2025120616332708300_hem2025000722C31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","article-title":"TET2 guards against unchecked BATF3- induced CAR T cell expansion","volume":"615","author":"Jain","year":"2023","journal-title":"Nature"},{"issue":"6537","key":"2025120616332708300_hem2025000722C32","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"issue":"9","key":"2025120616332708300_hem2025000722C33","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025120616332708300_hem2025000722C34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"issue":"10254","key":"2025120616332708300_hem2025000722C35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"2025120616332708300_hem2025000722C36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2025120616332708300_hem2025000722C37","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"16","key":"2025120616332708300_hem2025000722C38","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u200a\u2009\u00d7\u2009\u200aCD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"13","key":"2025120616332708300_hem2025000722C39","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"2025120616332708300_hem2025000722C40","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"2025120616332708300_hem2025000722C41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2024014171","article-title":"Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network","volume":"9","author":"Battiwalla","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2025120616332708300_hem2025000722C42","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300213","article-title":"CAR T-cell immunotherapy in minority patients with lymphoma","volume":"3","author":"Ghilardi","year":"2024","journal-title":"NEJM Evid"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/334\/2470086\/334rojek.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/334\/2470086\/334rojek.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:33:37Z","timestamp":1765056817000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/334\/556924\/Emerging-immunotherapy-advances-for-non-Hodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000722","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}